{"classes":[{"categories":[{"measurements":[{"comment":"Insufficient number of patients with the death event","groupId":"OG000","lowerLimit":"3.8","upperLimit":"NA","value":"6.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"On study date until death from any cause","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants receive avelumab by IV infusion following pretreatment with H1 blockers and acetaminophen once every 2 weeks.\n\nAvelumab: Avelumab through a vein once every 2 weeks","id":"OG000","title":"Avelumab Monotherapy"}],"paramType":"MEDIAN","populationDescription":"all participants","reportingStatus":"POSTED","timeFrame":"Every 3 months after completing treatment up to 5 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}